Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadruple ART in Acute HIV-1 Infection
NCT00002233Phase 2Completed
- Sponsor
- GSK
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lamivudine, abacavir, amprenavir and indinavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by GSK. Primary endpoints: Safety and Tolerability at 48 weeks, Plasma HIV-1 RNA levels at 48 weeks and 1 more. Status: completed.
02
Drugs
lamivudineabacaviramprenavirindinavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00002233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002233.